<DOC>
	<DOCNO>NCT01462474</DOCNO>
	<brief_summary>RATIONALE : Famitinib tyrosin-inhibitor agent target c-Kit , VEGFR2 , PDGFR , VEGFR3 , Flt1 Flt3 . Phase I study mono famitinib show drug 's toxicity manageable . PURPOSE : This phase I trial study safety tolerance concurrent chemoradiotherapy famitinib patient locally advanced nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Concurrent Chemoradiotherapy With Famitinib Patients With Locally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Histologically confirm nasopharyngeal differentiation undifferentiation carcinoma , WHO II III Newly diagnose T34N1（exception metastatic uni bil retropharyngeal lymph node N1） TN23 ( 7th UICC/AJCC ) locally advanced nasopharyngeal carcinoma 1865 year age ECOG performance status 0 1 Life expectancy 6 month At least one measurable lesion : MRI scan large 10 mm diameter , malignant lymph node large 10 mm short axis Female : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test article . Child bear potential , negative urine serum pregnancy test result initiate Famitinib . Male : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test article . Signed date informed consent . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . Before time second malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Any factor influence usage oral administration Known Spinal Cord compression disease brain pia mater CT /MRI Screening Imageology show tumor lesion le 5 mm great vessel ( internal carotid jugular vein ) Hemoglobin &lt; 90g/L , platelet &lt; 100×10^9/L , neutrophil &lt; 2×10^9/L , total bilirubin ≥ 1.25×the upper limit normal ( ULN ) , ALT\AST ≥ 1.5x ULN ) , serum creatine ＞ 1x ULN , creatinine clearance rate &lt; 60ml/min , Cholesterol ＞ 7.75 mmol/L triglyceride ＞ 3 mmol/L , LVEF : &lt; LLN Hypertensive ( 140/90 mmHg ) , class I ( NCI CTCAE 3.0 ) myocardial ischemia , arrhythmia ( include QTcF : male ≥ 450 m , female ≥470 m ) , cardiac insufficiency URT : urine protein ≥ ++ ＞ 1.0 g 24 h Longterm untreated wound fracture PT , APTT , TT , Fbg abnormal , hemorrhagic tendency ( eg . active peptic ulcer disease ) receive therapy thrombolysis anticoagulation Before first treatment occur artery / venous thromboembolic event , cerebral vascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism , etc Preexisting thyroid dysfunction , even use medical therapy , thyroid function maintain normal range Abuse Psychiatric drug dysphrenia Subject Viral hepatitis type B type C Subject immunodeficiency : HIV positive , acquire immunodeficiency , congenital immunodeficiency , organ transplantation With drug CYP3A4 inhibitor , inducer , substrate Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Concurrent Chemoradiotherapy</keyword>
</DOC>